AL-18 series (Advenchen)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameAL-18 series (Advenchen)
Drug Alias NameBcr-Abl tyrosine kinase inhibitors (Advenchen)AL-1842
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAdvenchen Laboratories Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdvenchen Laboratories Llc
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A